Literature DB >> 28634176

Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels.

Sarah Costantino1,2, Francesco Paneni1,2, Rodolfo Battista3, Lorenzo Castello4, Giuliana Capretti4, Sergio Chiandotto4, Luigi Tanese5, Giulio Russo6, Dario Pitocco5, Gaetano A Lanza6, Massimo Volpe4,7, Thomas F Lüscher2, Francesco Cosentino8.   

Abstract

Intensive glycemic control (IGC) targeting HbA1c fails to show an unequivocal reduction of macrovascular complications in type 2 diabetes (T2D); however, the underlying mechanisms remain elusive. Epigenetic changes are emerging as important mediators of cardiovascular damage and may play a role in this setting. This study investigated whether epigenetic regulation of the adaptor protein p66Shc, a key driver of mitochondrial oxidative stress, contributes to persistent vascular dysfunction in patients with T2D despite IGC. Thirty-nine patients with uncontrolled T2D (HbA1c >7.5%) and 24 age- and sex-matched healthy control subjects were consecutively enrolled. IGC was implemented for 6 months in patients with T2D to achieve a target HbA1c of ≤7.0%. Brachial artery flow-mediated dilation (FMD), urinary 8-isoprostaglandin F2α (8-isoPGF2α), and epigenetic regulation of p66Shc were assessed at baseline and follow-up. Continuous glucose monitoring was performed to determine the mean amplitude of glycemic excursion (MAGE) and postprandial incremental area under the curve (AUCpp). At baseline, patients with T2D showed impaired FMD, increased urinary 8-isoPGF2α, and p66Shc upregulation in circulating monocytes compared with control subjects. FMD, 8-isoPGF2α, and p66Shc expression were not affected by IGC. DNA hypomethylation and histone 3 acetylation were found on the p66Shc promoter of patients with T2D, and IGC did not change such adverse epigenetic remodeling. Persistent downregulation of methyltransferase DNMT3b and deacetylase SIRT1 may explain the observed p66Shc-related epigenetic changes. MAGE and AUCpp but not HbA1c were independently associated with the altered epigenetic profile on the p66Shc promoter. Hence, glucose fluctuations contribute to chromatin remodeling and may explain persistent vascular dysfunction in patients with T2D with target HbA1c levels.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28634176     DOI: 10.2337/db17-0294

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

1.  Ly6C+ Inflammatory Monocyte Differentiation Partially Mediates Hyperhomocysteinemia-Induced Vascular Dysfunction in Type 2 Diabetic db/db Mice.

Authors:  Pu Fang 方璞; Xinyuan Li 李欣源; Huimin Shan 单慧敏; Jason J Saredy; Ramon Cueto; Jixiang Xia 夏继祥; Xiaohua Jiang 蒋晓华; Xiao-Feng Yang 杨晓峰; Hong Wang 王虹
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-01       Impact factor: 8.311

Review 2.  Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.

Authors:  Sarah Costantino; Peter Libby; Raj Kishore; Jean-Claude Tardif; Assam El-Osta; Francesco Paneni
Journal:  Eur Heart J       Date:  2018-12-14       Impact factor: 29.983

Review 3.  New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk.

Authors:  Jin J Zhou; Daniel S Nuyujukian; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2021-03-02       Impact factor: 2.931

Review 4.  Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk.

Authors:  Alessandro Mengozzi; Nicola Riccardo Pugliese; Stefano Masi; Agostino Virdis; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-12-02

Review 5.  Epigenetic modifications in metabolic memory: What are the memories, and can we erase them?

Authors:  Zhuo Chen; Rama Natarajan
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-04       Impact factor: 5.282

6.  The initial glycemic variability is associated with early neurological deterioration in diabetic patients with acute ischemic stroke.

Authors:  Jiaojie Hui; Jianping Zhang; Xuqiang Mao; Zaiwang Li; Xinxin Li; Fengyun Wang; Tao Wang; Qingfang Yuan; Sunwei Wang; Mengjia Pu; Guangjun Xi
Journal:  Neurol Sci       Date:  2018-06-05       Impact factor: 3.307

7.  Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes.

Authors:  Kristina M Utzschneider; Tonya N Johnson; Kara L Breymeyer; Lisa Bettcher; Daniel Raftery; Katherine M Newton; Marian L Neuhouser
Journal:  J Diabetes Complications       Date:  2020-04-18       Impact factor: 2.852

Review 8.  Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.

Authors:  Nazha Hamdani; Sarah Costantino; Andreas Mügge; Djamel Lebeche; Carsten Tschöpe; Thomas Thum; Francesco Paneni
Journal:  Eur Heart J       Date:  2021-05-21       Impact factor: 29.983

9.  Assessment and pathophysiology of microvascular disease: recent progress and clinical implications.

Authors:  Stefano Masi; Damiano Rizzoni; Stefano Taddei; Robert Jay Widmer; Augusto C Montezano; Thomas F Lüscher; Ernesto L Schiffrin; Rhian M Touyz; Francesco Paneni; Amir Lerman; Gaetano A Lanza; Agostino Virdis
Journal:  Eur Heart J       Date:  2021-07-08       Impact factor: 29.983

10.  The Epigenome in Atherosclerosis.

Authors:  Sarah Costantino; Francesco Paneni
Journal:  Handb Exp Pharmacol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.